Pharmaceuticals Current Events | Pharmaceuticals News
|
|
|
Sort By:
Page Views | Date |
Xerion Pharmaceuticals Enters Into Option Agreement For Cancer Targets From Tufts University
Martinsried, Germany and Cambridge, MA, February 26, 2003 - Xerion Pharmaceuticals announced today that it has acquired exclusive rights to cancer targets resulting from the collaboration between Xerion and the laboratory of Daniel G. Jay, Ph.D., Professor of Physiology at Tufts University. Xerion plans to generate therapeutic antibodies against... view more... (2003-02-26)
Cerep Announces Drug Discovery Service Contract with Solvay
Rueil-Malmaison, August 28, 2000 - Cerep SA today announced a three year drug discovery collaboration with Solvay Pharmaceuticals. Under terms of the worldwide collaboration, Solvay will use all elements of Cerep’s technology platform for optimization and selection of drug candidates. Cerep will provide its High Throughput Screening and... view more... (2000-08-29)
New collaboration between Amersham Biosciences and Affibody increases potential in protein purification
Under the agreement, the two companies will work to develop affinity-based products for use in the production processes for protein-based pharmaceuticals. The development of these products will be based on Affibodies™, a novel class of small, robust affinity proteins designed to bind desired protein targets. Financial details of the... view more... (2002-03-06)
Cost-effectiveness of drugs may vary across borders
A study published in the journal Value in Health reviews variations in estimates of cost-effectiveness of pharmaceuticals from country to country. Data showed that the results seen in one country are not necessarily applicable in another and that decision makers need to interpret data from other countries very carefully. view more (2005-04-14)
Imprint's DepotOne needle achieves CE Mark
Imprint Pharmaceuticals (www.imprintpharma.com) is pleased to announce that its DepotOne needle technology has received its CE Mark and is now cleared for use in Europe. This CE Approval means that the DepotOne needle can be incorporated into clinical studies and existing products with minimal additional regulatory work. view more (2004-10-11)
1 step closer to green chemistry and improved pharmaceuticals
Proteins are the workhorses of our cells. They help to digest our food, are at the core of our immune system, and literally shape our body from top to toe. view more (2008-06-25)
Prolonged use of ramipril prevents stroke
Patients who are at high risk of stroke should be treated with the drug ramipril, irrespective of their initial blood pressure levels and in addition to other preventive treatments such as blood pressure lowering agents or aspirin, finds a study in this week’s BMJ. view more (2002-03-20)
UCSB researchers discover new biotechnology to identify
Researchers at UC Santa Barbara have developed a new biotechnology that enables scientists to identify and engineer protease substrates, giving them the means of crafting pharmaceuticals to outsmart disease. view more (2006-05-02)
Effects of the illegal use of pharmaceutical products in animal production on human health
The use of drugs/pharmaceuticals in cattle rearing is the object of a recent study, carried out by two researchers from the Centro de Estudos Farmac'™uticos, Laborat'³rio de Bromatologia, Hidrologia e Nutri'§'£o (Pharmaceutical Study Centre, Bromatology, Hydrology and Nutrition Laboratory) at the Pharmacy Faculty of Coimbra University.... view more... (2002-09-13)
atugen AG and metaGen Pharmaceuticals Sign Target Validation Agreement
Berlin, Germany, February 11, 2003 - atugen AG and metaGen Pharmaceuticals GmbH announced today that they have signed an agreement to evaluate the application of atugen's target validation technology in research and development of metaGen's novel cancer drug targets. Under the terms of the agreement atugen will select and screen specially designed... view more... (2003-02-11)
Nexavar shown to significantly extend survival for patients with advanced liver cancer
Bayer Pharmaceuticals Corporation (NYSE: BAY) and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that an independent data monitoring committee (DMC) has reviewed the safety and efficacy data from the companies' pivotal Phase 3 trial in patients with advanced hepatocellular carcinoma (HCC), or primary liver cancer. view more (2007-02-13)
New form of intravenous iron treats anemia in chronic kidney disease patients on dialysis
Ferumoxytol, a novel intravenous form of iron that permits rapid administration of large doses, has been shown to be effective for treating iron deficiency in chronic kidney disease (CKD) patients on dialysis, according to a clinical trial appearing in the February 2009 issue of the Clinical Journal of the American Society Nephrology (CJASN). view more (2009-01-28)
UK industry is the loser from parallel trade in pharmaceuticals
The shipment of bona fide pharmaceutical drugs into Britain from Europe may cost the UK pharmaceutical industry more than £770million a year. The net effect on the UK economy as a whole, taking into account the benefit to consumers of lower pharmaceutical prices, may be more than £290million. In addition it may undermine the long-term... view more... (2004-03-19)
Combating counterfeit Rx from China
Agencies worldwide are cracking down on counterfeit pharmaceuticals, and much of the focus has been on China, where an official was recently executed for approving fake medicines. view more (2007-07-17)
Lords Call For Faster Progress Towards Cannabis-Based Medicine
Progress towards a cannabis-based medicine for conditions such as multiple sclerosis is too slow, says the House of Lords Science & Technology Committee in a report published today [22 March]. The use of cannabis for any purpose other than scientific research is currently illegal. In November 1998 the Lords Committee recommended, on the basis... view more... (2001-03-22)
NMR researchers unlock hydrogen's secrets to spot polymorphism in pharmaceuticals
Researchers at the University of Warwick and Astra Zeneca have found a new way to use solid-state NMR equipment to crack the secrets of hydrogen atoms and thus spot unwanted polymorphs in pharmaceuticals. view more (2007-10-18)
Fine-tuning an anti-cancer drug
Cancer remains a deadly threat despite the best efforts of science. New hopes were raised a few years ago with the discovery that the uncontrolled growth of cancer cells could be thwarted by blocking the action of proteasomes. view more (2009-08-19)
The government of Catalunya sets up Spain's first Bioincubator in the Barcelona Science Park
Today the Autonomous Government of Catalonia and the University of Barcelona (UB) have opened the first bioincubator in Spain. Located in the Parc Cient'fic de Barcelona (PCB)(Barcelona Science Park), the main goal of this incubator is to provide a scientific and technological support infrastructure for new business projects in the biotechnology... view more... (2002-07-19)
DISTINGUISHED SERVICE AWARD BESTOWED - Pharmaceutical leader applauded for dedicated service to international Society
16 May 2003, London, UK: Dr Barry Porter, Chief Operating Officer, Curidium Ltd, will be awarded with the prestigious Society of Chemical Industry (SCI) Distinguished Service Award today at SCI International Headquarters in Belgrave Square, London, UK. The award will be given in recognition of Dr Porter's extensive service to the Society. He has... view more... (2003-05-16)
Researchers describe protease inhibitor that may aid in diabetic retinopathy treatment
Researchers from Joslin Diabetes Center, Boston, and ActiveSite Pharmaceuticals, Inc., San Francisco, announced today that they have demonstrated that a specific inhibitor of the protease plasma kallikrein, ASP-440, developed by ActiveSite Pharmaceuticals, may provide a new therapeutic approach for treatment of diabetic retinopathy, the most... view more... (2009-01-22)
|
|
|
|
Sort By:
Page Views | Date |
|
